Breathing life into BMY's reject

York Medical Inc. is going to get a chance to see if it has better instincts than Bristol-Meyers Squibb Corp. York has acquired from the University of Manitoba and CancerCare Manitoba exclusive rights to a small molecule chemopotentiator, Tesmilifene, that had been tested and discarded by BMY. York based its decision on data that came out after the pharma company made its choice.

Tesmilifene, an intracellular histamine antagonist originally known as DPPE, potentially has cytotoxic activity in tumor cells and cytoprotective action in normal cells exposed to chemotherapeutic agents through its modulatory activity on the cytochrome P450 system...